

Supervisory board extends Dr. Harald Schwager's contract

September 22, 2021

- Deputy chairman of the executive board appointed until 2025
- Continuity on the executive board ensured for years
- Focus on the future development of the chemicals business with innovative products and solutions

Matthias Ruch
Head of External Communications
Phone +49 201 177 3315
Mobile +49 174 325 9942
Matthias.Ruch@evonik.com

Essen, Germany. Dr. Harald Schwager will be shaping the development of Evonik for a further three years as deputy chairman of the executive board. The supervisory board has already decided to extend his contract until 2025. It was originally due to expire next fall. Schwager (61) has a PhD in chemistry and joined Evonik from BASF in 2017. His responsibilities on Evonik's executive board include chemicals and innovation. In addition, he is responsible for the Asia growth region.

Having extended the contract with executive board chairman Christian Kullmann in June of this year, this step ensures the long-term personnel continuity of Evonik's executive board. Schwager thanked the supervisory board for its trust in him: "In the coming years, I will continue to do everything in my power to drive forward Evonik's innovative capability and position it as a best-in-class specialty chemicals company," said Schwager. "That will include a special focus on developing sustainable solutions for customers, which we refer to as Next Generation Solutions."

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Fax +49 201 177-3475
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Thomas Wessel, Ute Wolf

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.